Last reviewed · How we verify
P2Y12 inhibitor
P2Y12 inhibitor, marketed by Insel Gruppe AG in collaboration with University Hospital Bern, holds a significant position in the antiplatelet therapy market. The drug's key strength lies in its mechanism of action, which effectively inhibits platelet aggregation, a critical factor in preventing thrombotic events. The primary risk to the drug's market position is the key composition patent expiry in 2028, which could lead to increased competition from generic alternatives.
At a glance
| Generic name | P2Y12 inhibitor |
|---|---|
| Also known as | antiplatelet agent, clopidogrel, prasugrel, ticagrelor, Clopidogrel |
| Sponsor | Insel Gruppe AG, University Hospital Bern |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- OPTIA-AF Trial: Rhythm-Guided Antithrombotic Strategy After AF Ablation (PHASE4)
- Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI (PHASE4)
- REperfusion With P2Y12 Inhibitors in Addition to mEchanical thRombectomy for perFUsion Imaging Selected Acute Stroke patiEnts (PHASE3)
- The Switching Antiplatelet-9 (SWAP-9) Study (PHASE4)
- Aspirin and a PoTent P2Y12 Inhibitor Versus Aspirin and Clopidogrel in Patients Undergoing PCI for Complex Lesion (PHASE4)
- STEMI Treated With a Polymer-free Sirolimus-coated Stent and P2Y12 Inhibitor-based SAPT Versus Conventional DAPT (NA)
- Safety and Efficacy of De-escalation Dual Antiplatelet Therapy After BioFreedom™ Stenting in ACS Patients With Moderate-to-high Ischemic and High Bleeding Risk (NA)
- PCI With Guideline-Directed Medical Therapy for HFpEF Patients With Ischemic Cardiomyopathy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- P2Y12 inhibitor CI brief — competitive landscape report
- P2Y12 inhibitor updates RSS · CI watch RSS
- Insel Gruppe AG, University Hospital Bern portfolio CI